Home › Companies › SUPERNUS PHARMACEUTICALS INC. › 2023-2024

SUPERNUS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and SUPERNUS PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-17 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
303Asset managers
1,844Fund votes
2024-06-14Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SUPERNUS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SUPERNUS PHARMACEUTICALS INC.

These tallies are SUPERNUS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SUPERNUS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-14
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Georges Gemayel, Ph.D	48,410,580	--	--	2,121,505	1,945,574	Majority: yes
Elect Director: Bethany L. Sensenig	48,568,282	--	--	1,963,803	1,945,574	Majority: yes
Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.	48,217,539	2,290,237	24,309	--	1,945,574	Majority: yes
Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2024.	52,182,042	272,906	22,711	--	0	Majority: yes
Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc	45,522,166	4,972,675	37,244	--	1,945,574	Majority: yes

Source: SUPERNUS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-17 — read the filing on EDGAR.

How asset managers voted at the SUPERNUS PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 303 asset managers that disclosed a SUPERNUS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SUPERNUS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. to approve, on a non-binding basis, the compensation paid to our named executive officers;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 12 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 48,217,539AGAINST: 2,290,237

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.”): 48,217,539 for, 2,290,237 against, per its Form 8-K filed 2024-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,723,356 outstanding shares: 88% for, 4% against (92% of the company cast a for/against vote).

The 301 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 96%

FOR: 96.4%AGAINST: 3.5%ABSTAIN: 0.0%NOT VOTED: 0.0%UNKNOWN: 0.0%

Largest asset managers voting on “to approve, on a non-binding basis, the compensation paid to our named executive officers;” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
BlackRock	7,775,093	11,690	For
Vanguard	7,130,070	0	For
ARMISTICE CAPITAL, LLC	2,928,621	0	For
State Street	2,831,017	585	For
Dimensional	2,494,679	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	2,447,445	0	For
Delaware/Macquarie	2,074,747	0	For
Polar Capital Holdings Plc	1,940,510	0	For
Stephens Investment Management Group LLC	1,440,057	0	For
Fidelity	1,259,592	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,257,024	0	For
Charles Schwab	1,191,905	0	For
GW&K Investment Management, LLC	1,095,294	8,323	For
Aristotle Capital Boston, LLC	978,629	0	For
Victory Capital	952,883	0	For
CONGRESS ASSET MANAGEMENT CO /MA	882,956	0	For
Invesco	882,239	0	For
Renaissance	814,787	0	For
Loomis Sayles	800,935	0	For
ASHFORD CAPITAL MANAGEMENT INC	737,165	0	For
T. Rowe Price	593,683	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	570,000	0	For
Northern Trust	541,320	43	For
Columbia Threadneedle	515,837	0	For
PICTET ASSET MANAGEMENT SA	483,468	0	For

Showing the 25 largest of 301 asset managers. See all 301 in the interactive database.

2. to consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the plan and make certain technical updates; and

COMPENSATIONMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 45,522,166AGAINST: 4,972,675

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc”): 45,522,166 for, 4,972,675 against, per its Form 8-K filed 2024-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,723,356 outstanding shares: 83% for, 9% against (92% of the company cast a for/against vote).

The 99 asset managers below cast 93% of the shares they voted on this item FOR (25,157,250 for, 1,874,752 against).

FOR 93%

FOR: 25,157,250 (93.0%)AGAINST: 1,874,752 (6.9%)ABSTAIN: 17,193 (0.1%)UNKNOWN: 1,822 (0.0%)

Largest asset managers voting on “to consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to ” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	6,977,657	0	0	For
BlackRock	5,666,093	0	0	For
Dimensional	2,250,559	0	0	For
Delaware/Macquarie	2,074,747	0	0	For
Fidelity	1,251,626	0	0	For
State Street	1,891	923,200	0	Against
Loomis Sayles	800,935	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	570,000	0	0	For
Charles Schwab	567,392	0	0	For
Columbia Threadneedle	515,837	0	0	For
Invesco	430,653	0	0	For
Victory Capital	334,798	0	0	For
AMG FUNDS	0	328,174	0	Against
Brighthouse	274,759	0	17,193	For
MoA Funds Corp	273,630	0	0	For
Bridge Builder Trust	262,734	1,536	0	For
T. Rowe Price	234,311	0	0	For
TIAA	226,932	0	0	For
Tributary Funds, Inc.	0	225,005	0	Against
John Hancock	62,502	126,889	0	Against
Lincoln Financial	135,028	41,190	0	For
THIRD AVENUE TRUST	0	159,717	0	Against
Jackson National	131,114	0	0	For
Equitable	125,824	0	0	For
CARILLON SERIES TRUST	121,235	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

3. to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Georges Gemayel, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 48,410,580WITHHELD: 2,121,505

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Georges Gemayel, Ph.D”): 48,410,580 for, 2,121,505 withheld, per its Form 8-K filed 2024-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,723,356 outstanding shares: 88% for, 4% withheld (92% of the company cast a for/withheld vote).

The 98 asset managers below cast 100% of the shares they voted on this item FOR (26,214,022 for, 0 against).

FOR 97%

FOR: 26,214,022 (96.8%)ABSTAIN: 874,729 (3.2%)UNKNOWN: 1,822 (0.0%)

Largest asset managers voting on “to elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	6,977,657	0	For
BlackRock	5,666,093	0	For
Dimensional	2,250,559	0	For
Delaware/Macquarie	2,074,747	0	For
Fidelity	1,251,626	0	For
State Street	924,798	293	For
Loomis Sayles	800,935	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	570,000	0	For
Charles Schwab	567,392	0	For
Columbia Threadneedle	515,837	0	For
Invesco	0	430,653	Abstain
Victory Capital	334,798	0	For
AMG FUNDS	328,174	0	For
Brighthouse	241,067	50,885	For
MoA Funds Corp	273,630	0	For
Bridge Builder Trust	264,270	0	For
T. Rowe Price	0	234,311	Abstain
TIAA	226,932	0	For
Tributary Funds, Inc.	225,005	0	For
John Hancock	189,391	0	For
Lincoln Financial	176,218	0	For
THIRD AVENUE TRUST	159,717	0	For
Empower	112,838	39,636	For
Jackson National	131,114	0	For
Equitable	75,624	50,200	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

4. to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 52,182,042AGAINST: 272,906

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2024.”): 52,182,042 for, 272,906 against, per its Form 8-K filed 2024-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,723,356 outstanding shares: 95% for, 0.5% against (96% of the company cast a for/against vote).

The 98 asset managers below cast 99.9% of the shares they voted on this item FOR (27,071,482 for, 76 against).

FOR 99.9%

FOR: 27,071,482 (99.9%)AGAINST: 76 (0.0%)ABSTAIN: 17,193 (0.1%)UNKNOWN: 1,822 (0.0%)

Largest asset managers voting on “to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	6,977,657	0	0	For
BlackRock	5,666,093	0	0	For
Dimensional	2,250,559	0	0	For
Delaware/Macquarie	2,074,747	0	0	For
Fidelity	1,251,626	0	0	For
State Street	925,015	76	0	For
Loomis Sayles	800,935	0	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	570,000	0	0	For
Charles Schwab	567,392	0	0	For
Columbia Threadneedle	515,837	0	0	For
Invesco	430,653	0	0	For
Victory Capital	334,798	0	0	For
AMG FUNDS	328,174	0	0	For
Brighthouse	274,759	0	17,193	For
MoA Funds Corp	273,630	0	0	For
Bridge Builder Trust	264,270	0	0	For
T. Rowe Price	234,311	0	0	For
TIAA	226,932	0	0	For
Tributary Funds, Inc.	225,005	0	0	For
John Hancock	189,391	0	0	For
Lincoln Financial	176,218	0	0	For
THIRD AVENUE TRUST	159,717	0	0	For
Empower	152,474	0	0	For
Jackson National	131,114	0	0	For
Equitable	125,824	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

5. to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Bethany L. Sensenig

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 48,568,282WITHHELD: 1,963,803

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bethany L. Sensenig”): 48,568,282 for, 1,963,803 withheld, per its Form 8-K filed 2024-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,723,356 outstanding shares: 89% for, 4% withheld (92% of the company cast a for/withheld vote).

The 97 asset managers below cast 100% of the shares they voted on this item FOR (26,469,869 for, 0 against).

FOR 98%

FOR: 26,469,869 (97.7%)ABSTAIN: 609,162 (2.2%)UNKNOWN: 1,822 (0.0%)

Largest asset managers voting on “to elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	6,977,657	0	For
BlackRock	5,666,093	0	For
Dimensional	2,250,559	0	For
Delaware/Macquarie	2,074,747	0	For
Fidelity	1,251,626	0	For
State Street	925,091	0	For
Loomis Sayles	800,935	0	For
PROFESSIONALLY MANAGED PORTFOLIOS	570,000	0	For
Charles Schwab	567,392	0	For
Columbia Threadneedle	515,837	0	For
Invesco	430,653	0	For
Victory Capital	334,798	0	For
AMG FUNDS	0	328,174	Abstain
Brighthouse	274,759	17,193	For
MoA Funds Corp	273,630	0	For
Bridge Builder Trust	264,270	0	For
T. Rowe Price	234,311	0	For
TIAA	226,932	0	For
Tributary Funds, Inc.	225,005	0	For
John Hancock	62,502	126,889	Abstain
Lincoln Financial	176,218	0	For
THIRD AVENUE TRUST	159,717	0	For
Empower	152,474	0	For
Jackson National	131,114	0	For
Equitable	125,824	0	For

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

95% Majority: yes · of votes cast

FOR 95%

FOR: 48,217,539AGAINST: 2,290,237

The 3 asset managers below cast 13% of the shares they voted on this item FOR (15,697 for, 105,186 against).

13%AGAINST 87%

FOR: 15,697 (13.0%)AGAINST: 105,186 (87.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
JPMorgan	0	65,550	Against
Empower	0	39,636	Against
ADVISORY RESEARCH INC	15,697	0	For

Largest SUPERNUS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of SUPERNUS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 54,723,356 shares outstanding at the time of that meeting.

Top SUPERNUS PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	BlackRock	14.23%
2	Vanguard	13.03%
3	ARMISTICE CAPITAL, LLC	5.35%
4	State Street	5.17%
5	Dimensional	4.56%
6	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	4.47%
7	Delaware/Macquarie	3.79%
8	Polar Capital Holdings Plc	3.55%
9	Stephens Investment Management Group LLC	2.63%
10	Fidelity	2.30%

Reported SUPERNUS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SUPERNUS PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock, Inc. and its affiliates	18.97%	DEF14A
BlackRock	15.90%	13F
Vanguard Group	11.05%	13F
Armistice Capital, LLC	8.50%	DEF14A
Jack A. Khattar +	7.21%	DEF14A
Macquarie Group Limited and its affiliates	5.00%	DEF14A
Dimensional Fund Advisors	4.67%	13F
State Street	3.73%	13F
Renaissance Technologies	2.44%	13F
Geode Capital	2.39%	13F

Percentages above are of 54,723,356 shares outstanding, as reported by SUPERNUS PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUPERNUS PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At SUPERNUS PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-14, in the 2023-2024 proxy season, 303 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,844 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — to approve, on a non-binding basis, the compensation paid to our named executive officers; — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUPERNUS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-17.

SUPERNUS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.